KTTA — Pasithea Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Pasithea Therapeutics Announces Completion Of Cohort 7 In Ongoing Phase 1 Trial Of Pas-004
Brief: Pasithea Therapeutics Says Positive PAS-004 Tablet Pharmacokinetic Data In Ongoing Phase 1/1B Trial In Adult NF1 Patients
Brief: Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response
Brief: Pasithea Therapeutics Announces Enrollment Of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation
Brief: Pasithea Completes Enrollment, Dosing of First Cohort in PAS-004 Phase 1/1B NF1 Trial
Brief: Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site
Brief: Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering
Brief: Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing
Brief: Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer
Brief: Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Brief: Pasithea Therapeutics Entered Into Sales Agreement Relating To Sale Of Shares Of Common Stock Of Up To $2.1 Million From Time To Time
Brief: Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation
U.S. STOCKS ON THE MOVE-ASML Holding, Meta, Crocs
Pasithea Therapeutics rises on positive early-stage data from cancer drug
Brief: Pasithea Therapeutics Announces Positive Efficacy Data From Its Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer
Brief: Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial
Brief: Pasithea Therapeutics Announces Opening Of Enrollment In The U.S. For Its Phase 1 Trial Of Pas-004
Brief: Pasithea Therapeutics Says Co Received A Letter From Nasdaq Stating That It Regained Compliance With Minimum Bid Price Requirement
Brief: Pasithea Therapeutics Announces FDA Acceptance Of IND Application To Evaluate Pas-004 In Advanced Cancer Patients